Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray

Perrigo Company has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc. Terms of the settlement are confidential.

Annual market sales for the 12-months ending June 2019 were $90 million as measured by IQVIA™.

Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to introduce new generic products that provide savings to patients and healthcare systems."

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.